Today, we are excited to announce positive initial data from the Phase 2 study evaluating bemnifosbuvir, our oral nucleotide polymerase inhibitor in combination with ruzasvir, an oral NS5A inhibitor, for the treatment of #HCV at #EASL2024. https://lnkd.in/eKEsKXuP
Atea Pharmaceuticals, Inc
生物技术研究
Boston，Massachusetts 2,668 位关注者
Discovery & development of breakthrough therapies for COVID-19 patients and severe viral diseases
关于我们
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment.
- 网站
-
https://www.ateapharma.com/
Atea Pharmaceuticals, Inc的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Boston，Massachusetts
- 类型
- 上市公司
- 创立
- 2014
地点
-
主要
获取路线
225 Franklin St
Suite, 2100
US，Massachusetts，Boston，02110
Atea Pharmaceuticals, Inc员工
动态
-
We're #hiring a new Director, Regulatory CMC in Massachusetts. Apply today or share this post with your network.
-
Today, we are pleased to announce enrollment completion in the global Ph3 SUNRISE-3 trial evaluating bemnifosbuvir, our oral nucleotide antiviral, for the treatment of #COVID19. https://lnkd.in/g3yek4qz
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients | Atea Pharmaceuticals, Inc.
ir.ateapharma.com